Výsledky vyhledávání - "C G, Leichman"

Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin (FOLFOX4) as first-line therapy for patients with advanced colorectal cancer

Autor: Patricia Hentschel, John F. Gill, Paul S. Ritch, Sandeep K. Malik, C. G. Leichman, Stefan Madajewicz, Donald J. Higby, M Qaseem Khan, Luping Zhao, David M. Waterhouse, Steven J. Nicol

Publikováno v: Investigational New Drugs. 30:772-778

Purpose To assess safety and efficacy of folinic acid, 5-fluorouracil, gemcitabine (FFG) and folinic acid, fluorouracil, oxaliplatin (FOLFOX4) regimens with added bevacizumab as first-line treatment in patients with advanced colorectal cancer (CRC).

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a34b1e1956970bb8eff39caf98e38a2
https://doi.org/10.1007/s10637-010-9598-9

Zobrazit plný text záznamu

A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863

Autor: Gini F. Fleming, John L. Marshall, C. Enders Klein, M. Villalona, Raymond J. Hohl, Donna Hollis, John C. Byrd, Helen Kastrissios, Joel Ramirez, Daniel R. Budman, C. G. Leichman, Mark J. Ratain, G. L. Rosner, Alan P. Venook

Publikováno v: Annals of Oncology. 14:1783-1790

BACKGROUND To ascertain if hepatic or renal dysfunction or prior pelvic radiation (XRT) leads to increased toxicity at a given dose of irinotecan and to characterize the pharmacokinetics of irinotecan and its major metabolites in patients with hepati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be53ee61581fb1aa7bf6228e0cbb9714
https://doi.org/10.1093/annonc/mdg493

Zobrazit plný text záznamu

Biochemical Modulation of 5-Fluorouacil Through Dihydropyrimidine Dehydrogenase Inhibition: a Southwest Oncology Group Phase II Trial of Eniluracil and 5-Fluorouracil in Advanced Resistant Colorectal Cancer

Autor: Kari Chansky, James L. Abbruzzese, Michael Doukas, G. Thomas Budd, Jeffrey K. Giguere, John S. Macdonald, C. G. Leichman

Publikováno v: Investigational New Drugs. 20:419-424

To investigate the hypothesis that a systemic agent designed to inhibit dihydropyrimidine dehydrogenase (DPD), the first enzyme in the fluoropyrimidine degradative pathway, could improve the effective amount of 5-fluorouracil (5-FU) delivered to a tu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f191f84a002e63feeaaecc26a01ea8dc
https://doi.org/10.1023/a:1020662113061

Zobrazit plný text záznamu

Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin

Autor: Lawrence Leichman, Joaquina Baranda, Susan Groshen, Peter V. Danenberg, Kathleen D. Danenberg, C. G. Leichman, Ralf Metzger, Heinz-Josef Lenz, William D. Boswell, Matthew Tan

Publikováno v: Journal of Clinical Oncology. 15:3223-3229

PURPOSE Response rates to fluorouracil (5-FU)-based therapy remain low. As new, active agents are being tested, information regarding specific intratumoral genetic determinants of chemotherapy sensitivity or resistance can be used to plan therapy rat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b339bfd7a911bb3b42200abfc95ec4d
https://doi.org/10.1200/jco.1997.15.10.3223

Zobrazit plný text záznamu

Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study

Autor: Catherine M. Tangen, Geoffrey R. Weiss, Thomas R. Fleming, R F Holcombe, C. G. Leichman, B Ardalan, Franco M. Muggia, James H. Doroshow, A Mangalik, Frederick J. Meyers

Publikováno v: Journal of Clinical Oncology. 13:1303-1311

PURPOSE A variety of fluorinated pyrimidine-based regimens for the treatment of disseminated colorectal cancer have been presented in the medical literature. The Southwest Oncology Group designed a screening trial of seven regimens of fluorouracil (5

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2592c18f08cedba0703dafc723f6a62a
https://doi.org/10.1200/jco.1995.13.6.1303

Zobrazit plný text záznamu

Prolonged Infusion of Fluorinated Pyrimidines in Gastrointestinal Malignancies: A Review of Recent Clinical Trials

Autor: C. G. Leichman

Publikováno v: Cancer Investigation. 12:166-175

(1994). Prolonged Infusion of Fluorinated Pyrimidines in Gastrointestinal Malignancies: A Review of Recent Clinical Trials. Cancer Investigation: Vol. 12, No. 2, pp. 166-175.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22518073c7f4b9592d6d9d5df3b66793
https://doi.org/10.3109/07357909409024872

Zobrazit plný text záznamu

Phase I Study of (6R)-5, 10-Dideazatetrahydrofolate: a Folate Antimetabolite Inhibitory to De Novo Purine Synthesis

Autor: M S Ray, R G Moran, Steven M. Grunberg, C G Leichman, R L Nelson, R W Dyke, Franco M. Muggia

Publikováno v: JNCI Journal of the National Cancer Institute. 85:1154-1159

Background Cancer chemotherapy with folate antimetabolites has been traditionally targeted at the enzyme dihydrofolate reductase and is based on the requirement of dividing tumor cells for a supply of thymidylate and purines. However, a new compound,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::926c81a10afef09f447f9c5479b18bb2
https://doi.org/10.1093/jnci/85.14.1154

Zobrazit plný text záznamu

Prolonged Continuous Infusion of Fluorouracil With Weekly Bolus Leucovorin: A Phase II Study in Patients With Disseminated Colorectal Cancer

Autor: C. G. Leichman, Susan Groshen, C. P. Spears, Susan Jeffers, Peter J. Rosen, L Leichman

Publikováno v: JNCI Journal of the National Cancer Institute. 85:41-44

Background Biochemical modulation of bolus fluorouracil (5-FU) by addition of leucovorin to the treatment regimen has increased response in patients with disseminated colorectal cancer from fewer than 20% to more than 40%. In view of the short half-l

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5188250e4e91235bcbc2a730a5e7d74
https://doi.org/10.1093/jnci/85.1.41

Zobrazit plný text záznamu

Preoperative systemic chemotherapy followed by adjuvant postoperative intraperitoneal therapy for gastric cancer: a University of Southern California pilot program

Autor: R Radin, L Leichman, Loren Laine, M S Ray, Howard Silberman, C. G. Leichman, C P Spears, M Kiyabu, Franco M. Muggia, Steven C. Stain

Publikováno v: Journal of Clinical Oncology. 10:1933-1942

PURPOSE A clinical trial for patients with gastric cancer amenable to curative resection was undertaken to determine feasibility and response to preoperative systemic chemotherapy followed by postoperative intraperitoneal (IP) chemotherapy. METHODS A

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6e3301e8ba2a7c43936608e93bd4b16
https://doi.org/10.1200/jco.1992.10.12.1933

Zobrazit plný text záznamu

Biological Modification of protracted infusion of 5-fluorouracil with weekly leucovorin

Autor: C. P. Spears, C. G. Leichman, Susan Jeffers, Waugh W, L Leichman, Franco M. Muggia, Peter J. Rosen

Publikováno v: Cancer Chemotherapy and Pharmacology. 26:57-61

A clinical trial was designed to find the maximally tolerated dose of weekly leucovorin (LV) that could be combined with 4 weeks of protracted infusion (PI) of 5-fluorouracil (5FU) at a fixed dose of 200 mg/m2. A total of 36 patients with disseminate

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50fc8111a652b9e961acd272c13f352b
https://doi.org/10.1007/bf02940295

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání